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Abstract
Background: Artemisinin-based combination therapy is increasingly being adopted as first-line
antimalarial therapy. The choice of appropriate therapy depends on efficacy, cost, side effects, and
simplicity of administration.
Methods: the efficacy of fixed co-formulated (f) artesunate-sulfamethoxypyrazine-pyrimethamine
(AS+SMP f) administered at time intervals of 12 hours for a 24-hour therapy was compared with
the efficacy of the same drug given as a loose combination (AS+SMP l) with a dose interval of 24
hours for 3 days for the treatment of uncomplicated Plasmodium falciparum malaria in eastern
Sudan.
Results:  seventy-three patients (39 and 34 in the fixed and the loose regimen of AS+SMP
respectively) completed the 28-days of follow-up. On day 3; all patients in both groups were a
parasitaemic but one patient in the fixed group of AS+SMP f was still febrile.
Polymerase chain reaction genotyping adjusted cure rates on day 28 were 92.3% and 97.1% (P >
0.05) for the fixed and loose combination of AS+SMP respectively.
Three (4.1%) patients (one in the fixed and two patients in the loose group of AS+SMP) in the study
suffered drug-related adverse effects.
Gametocytaemia was not detected during follow-up in any of the patients.
Conclusion:  both regimens of AS+SMP were effective and safe for the treatment of
uncomplicated P. falciparum malaria in eastern Sudan. Due to its simplicity, the fixed dose one-day
treatment regimen may improve compliance and therefore may be the preferred choice.
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Background
There are almost 515 million episodes of clinical Plasmo-
dium falciparum malaria infections [1]. Malaria treatment
and control have been undermined by emergence and
spread of drug-resistant malaria worldwide hereby
increasing morbidity and mortality. World Health Organ-
ization's strategies to reduce malaria-related mortality
depend on early diagnosis and effective treatment with an
appropriate drug and now artemisinin-based combina-
tion therapies (ACTs) are recommended [2,3]. Malaria
causes up to 7.5 – 10 million cases and 35000 deaths
every year in Sudan [4]. Due to the spread of multi-drug
resistant  Plasmodium falciparum malaria in Sudan [5],
artesunate plus sulfadoxine-pyrimethamine (AS+SP) is at
this moment the recommended first-line treatment for
uncomplicated P. falciparum malaria.
The choice of an ACT in specific malaria-endemic areas
needs to take into account their efficacy, side effects, price
and mode of administration. Common ACT therapies last
for 3 days and in some instances the patient has to swal-
low up to 24 tablets. Sulfamethoxypyrazine (SM) is chem-
ically very close to sulfadoxine but has different
pharmacokinetics [6,7]. The high efficacy of sulfamethox-
ypyrazine-pyrimethamine (SMP) for treating P. falciparum
malaria had been demonstrated previously [8-10]. It is
expected that the combination of this drug with artesu-
nate will result in a highly efficacious treatment for P. fal-
ciparum malaria. The manufacturer's (Dafra Pharma, NV)
accomplished this combination and new treatment was
considered for use as a single dose per day over 3 days.
According to the pharmacokinetics property [6,7], it was
explored it would be possible to reduce the dosing inter-
val between each tablet to 12 h and therefore limit the
treatment duration to 24 hours. The objective of this trial
was to investigate the efficacy of this drug (AS+SMP as two
different regimens) in the treatment of uncomplicated P.
falciparum malaria, since no published data exists yet con-
cerning these drug combinations.
Patients and methods
The study was conducted in September-November 2005
at AL Sawagi ALganoubia health center in Kassala, eastern
Sudan. The area is characterized by low malaria transmis-
sion [11]. Febrile (temperature ≥ 37.5°C) patients with
uncomplicated P. falciparum malaria [12] andno history
of antimalarial drug use during the preceding two weeks
were recruited for the study. Pregnant women and
patients with mixed infections were excluded.
After obtaining informed consent from the patient or the
child's parents, a fixed questionnaire including relevant
socio-demographic characteristics, medical history, phys-
ical findings and investigations conducted was completed
for each patient.
Laboratory methods
Blood films were prepared, Giemsa-stained and examined
by 100× oil immersion fields. The parasite density was
counted against 200 leucocytes, assuming 8000 leuco-
cytes/μl. All slides were double-checked blindly and only
considered negative if no parasites were detected in 100
oil immersion fields. If gametocytes were seen, then the
count was extended to 500 leucocytes.
Three spots of blood were taken on filter-paper initially
and later if parasites reappeared microscopically during
the follow-up period to differentiate between re-infection
and recrudescence using nested PCR where FC 27 and ICI
alles of Primers from polymorphic P. falciparum mero-
zoite surface protein 1&2 (MSP1 & MSP2) were detected
[13,14].
Treatment and follow up
The manufacturers' (Dafra Pharma NV) instructions were
strictly followed. The patients were alternatively allocated
either to the fixed or the loose combination of AS+SMP.
The patients appointed to the fixed dose group were given
3 doses of AS+SMP f orally as a fixed combination (one
single tablet every 12 hours (a total treatment lasted 24
hours). The fixed dose tablets were available in three dif-
ferent dosage strengths, each one containing AS/SM/P mg
in different doses; 200/500/25 for adults (≥40 kg), 100/
250/12.5 for children and adolescents (16–39.9 kg) and
50/125/6.25 for babies and infants (≤15.9 kg).
The patients in the group receiving the loose combination
were also given the treatment according to their weight.
They received two different tablets which were colour-
coded for ease of administration: pink SMP tablets and
white AS tablets. Their treatment regimen lasted for three
days with intervals of 24 hours.
The tablets were crushed and dissolved in water for chil-
dren who were not able to swallow them. Subjects were
observed for vomiting for one hour; the full dose was
repeated for those who vomited within 30 min and half of
the dose was repeated if vomiting occurred between 30
and 60 minutes.
Follow-up and re-treatment
Patients were requested to come back on days 1, 2, 3, 7,
14, 21 and 28 and at any time they felt unwell. At each
visit, body temperature was measured and blood films
were prepared. Haemoglobin was measured on day 0 and
day 28. During the follow-up the patients were asked if
they suffered from side effects which could be expected
from the treatment (nausea, vomiting, abdominal pain,
dizziness and rash); these symptoms were considered to
be drug related if they had not been reported at the
patient's first presentation to the clinic.Annals of Clinical Microbiology and Antimicrobials 2006, 5:18 http://www.ann-clinmicrob.com/content/5/1/18
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The second-line treatment for uncomplicated P. falci-
parum  malaria in Sudan (Artemether-lumfantrine) was
given for treatment failures and the patients were fol-
lowed as above. Classification was done based on the fol-
lowing: Early Treatment Failures (ETF) in case of
significant parasitaemia at day 2 or 3 or parasites and fever
at day 3, Late Clinical Failures (LCF) for cases with para-
sites and fever during follow-up after day 3 and Late Para-
sitological Failures (LPF) for parasite infections with/
without fever during the follow-up period. Cases which
remained negative during follow-up were considered to
be Adequate Clinical and Parasitological Responses
(ACPR). These were modified WHO guidelines [12,15].
Statistics
Data were entered into a computer database and SPSS
software (SPSS Inc., Chicago, IL, USA) was used for statis-
tical analysis. The means (age, weight, temperature, hae-
moglobin and parasite count) were calculated for all the
patients and were compared between the patients in the
two arms of the study using student t-test, when the data
was normally distributed and by Mann-Whitney test if the
data was not normally distributed. Percentages were cal-
culated and compared for the patients by X2 test. P < 0.05
was regarded significant.
Ethics
The study received ethical clearance from the Ethical
board of the faculty of medicine, University of Khartoum.
Results
During the period of the study, eighty-one patients pre-
sented with uncomplicated P. falciparum malaria. Seventy-
three of them fulfilled the selection criteria and completed
the 28-days follow-up; 39 and 34 in the fixed and the
loose combinations of AS+SMP groups respectively. Eight
patients, three in the fixed and five in the loose group were
lost during the follow-up period because they changed
their addresses, figure 1.
Nine (12.3%) patients were children under five years of
age; 5 (12.8%) vs. 4 (11.8%) of them in the fixed and the
loose group of AS+MSP respectively. There was no signifi-
cant difference in the presenting age, weight, temperature,
parasite count and the haemoglobin level between the
two groups, table 1.
Three (4.1%) patients (one in the fixed dose and two in
the loose group of AS+SMP) in the study suffered drug-
related adverse effects (nausea, vomiting, diarrhea, itching
and dizziness), P > 0.05. However, these were mild and
resolved spontaneously.
On day 1; four (10.3%) vs. one (2.9%) patient was still
febrile, P > 0.05 and one (2.6%) was parasitaemic in the
fixed group of AS+SMP.
On day 3; one patient in the fixed group of AS+SMP was
still febrile but all the patients in both groups were apara-
sitaemic.
By day 28, four (10.3%) and one (2.9%) patient (P =
0.36) in the fixed and the loose group of AS+SMP respec-
tively, showed late treatment and parasitological failures,
the rest (89.7% vs. 97.1%) of the patients had an adequate
treatment response.
The results of parasite genotyping indicated that four (one
is the patient of loose and three patients in the fixed group
of AS+MSP) of these five treatment failures were cases of
recrudescence, where the parasites collected from each
relapse parasitaemia appeared to be identical, in terms of
their MSP1 & MSP2, to those collected pretreatment from
the same patients. The fifth relapse in the fixed group (day
28) was caused by re-infection, where the parasite alleles
were different.
Trial profile, showing number of patients enrolled, treated  and completing the 28 days of follow-up after the treatment  with fixed or loose combinations of AS+SMP Figure 1
Trial profile, showing number of patients enrolled, treated 
and completing the 28 days of follow-up after the treatment 
with fixed or loose combinations of AS+SMP
81 patients with uncomplicated 
falciparum malaria were
enrolled to the study. 
198 febrile patients were 
screened for malaria.
39 patients 
received loose
artesunate+
sulfamethoxypyr
azine
42 patients 
received fixed
dose artesunate+
sulfamethoxypy
razine -
5 patients 
lost the
follow-up
3 patients lost
the follow-up
34 patients 
completed the 28 
days follow-up
39 patients 
completed the 
28days follow-
One patient has 
treatment
failure
4 patients have 
treatment
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So PCR corrected cure rates were 92.3% and 97.1% (P >
0.05) for the two groups respectively.
At the beginning of the study, gametocytaemia was
detected in three patients (two in the fixed group), and it
was not detected during the follow-up in any of the
patients
Discussion
This is probably the first publication on efficacy of
AS+SMP in the treatment of uncomplicated falciparum
malaria. The high cure rate demonstrated for AS+-SMP
(>90%) in this study was expected because of the synergis-
tic effect of artesunate and SMP and potentially because of
the non-wide use of SMP as an antimalarial in this coun-
try. Previously high efficacy of SMP for the treatment of
uncomplicated P. falciparum malaria was reported in other
African countries [8-10].
Although the loose combinations of AS+SMP was slightly
(not significantly) more efficacious than the fixed one, the
fixed regimen of AS+SMP is most promising since it per-
mits reduction of the treatment duration to a maximum of
24 h. The mechanism of action of SM drug is the same as
of sulfadoxine(S), but its protein binding and elimination
half-life permit the new regimen to be developed in SM
rather than in SP [6,7,16]. The repeated loading dose of AS
is responsible for a drastic destruction of parasites whereas
the SMP combination enables to protract the favorable
effect, by continued inhibition of folic acid biosynthesis
in the parasite to over 15 days. The intake of only three
tablets, in combination with the short duration of the
treatment may be of paramount importance as an influ-
ence on the patients' compliance. The single dose of SP
was reported to have the best compliance among antima-
larial tested in Sudanese patients [17]. The treatments
with artemether + lumefantrine and AS + amodiaquine
(the therapies recommended by the WHO) suffer from
the large number of tablets (>20) and this may influenced
the compliance adversely. The fixed short interval regimen
of AS+SMP seems to be simple, effective and may enhance
the compliance. Yet, two parasite asexual life-cycles need
to be exposed to the artemisinin derivative to maximize
the reduction in parasite numbers and thereby minimiz-
ing the opportunity for resistance selection while provid-
ing optimum therapeutic responses [18]. However, single
high dose administration of 300 mg artesunate as one
dose, followed by mefloquine on day 24 and 30 h,
resulted in a 97% cure rate of malaria patients in Thailand
[19], which indicates that short treatment regimens of
artemisinin-derivatives with appropriate combinations
are effective.
In our study, the cure rates were 92.3% and 97.1 (P >
0.05) for both arms respectively. Treatment failures –
even, AS+SP treatment failure – has recently been reported
in the same area of the study [20]. Fewer mild side effects
were reported in both arms of the study, this itself might
improve the compliance of the patients towards the treat-
ment. Furthermore, these adverse effects were mild and
were not different from the adverse effects reported with
AS+SP in eastern Sudan [20,21]. Recently, high cure rates
and minimum adverse effects were reported among
patients with uncomplicated falciparum malaria treated
with SMP [10].
There was no gametocytaemia during the follow-up
period. High levels of gametocytaemia had been reported
in the eastern Sudan following non-artemisinin antima-
larials [22], but it had not been reported following ACTs
[21]. The ability of artesunate to reduce the post-treatment
gametocytaemia is important, as it may reduce transmis-
sion [23].
Conclusion
This was a small-sized study, larger size studies are
urgently needed to investigate the efficacy of this new for-
mulated drugs combinations. Both regimens of AS+SMP
were effective and safe for the treatment of uncomplicated
P. falciparum malaria in eastern Sudan. Due to its simplic-
Table 1: The base line (day 0) characteristic of the 73 patients who completed the 28 days of follow-up after the treatment with the 
fixed or loose combinations of AS+SMP
Fixed AS+SMP Group Loose AS+SMPGroup
No. of patients 39 34
MEAN VALUE AND (SD) For.
Age (years) 15.1 (12.5) 17.6 (11.1)
Weight (Kg) 33.8 (20.04) 39.8 (21.3)
Temperature (°C) 38.4 (0.8) 38.1 (0.93)
Parasite count (rings/μl) 18680.2 (26458.4) 21342.06 (23371.8)
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ity the fixed dose one-day treatment regimen may
improve compliance and therefore may be the preferred
choice
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